• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Unity Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    4/22/25 4:30:08 PM ET
    $UBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UBX alert in real time by email
    8-K
    false 0001463361 00014633612025-04-222025-04-22

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 22, 2025

     

     

    UNITY BIOTECHNOLOGY, INC.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

    001-38470

    26-4726035

    (State or other jurisdiction

    of incorporation)

    (Commission

    File Number)

    (IRS Employer

    Identification Number)

    285 East Grand Ave.

    South San Francisco, CA 94080

    (Address of principal executive offices, including Zip Code)

    Registrant’s telephone number, including area code: (650) 416-1192

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading Symbol(s)

    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

    UBX

    The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


    Item 2.02 Results of Operations and Financial Condition.

    On April 22, 2025, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Current Report on Form 8-K, including the attached Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

    Item 9.01 Financial Statements and Exhibits.

    Reference is made to the Exhibit Index attached hereto.

     

    EXHIBIT INDEX

    Exhibit No.

    Description

     

     

     

    99.1

    Press release dated April 22, 2025.

     

     

     

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    UNITY BIOTECHNOLOGY, INC.

     

     

     

    Date: April 22, 2025

    By:

    /s/ Anirvan Ghosh

     

     

    Anirvan Ghosh, Ph.D.

     

     

    Chief Executive Officer

     


    Get the next $UBX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UBX

    DatePrice TargetRatingAnalyst
    8/22/2024$8.00Buy
    Rodman & Renshaw
    11/16/2023$2.00 → $4.00Neutral → Outperform
    Wedbush
    1/4/2022$4.00Neutral → Buy
    Roth Capital
    1/4/2022Neutral → Buy
    ROTH Capital
    11/10/2021$5.00 → $7.00Neutral → Buy
    Mizuho
    6/28/2021Sell → Buy
    Citigroup
    6/28/2021$6.00Sell → Buy
    Citigroup
    More analyst ratings

    $UBX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

      SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the Company will present 36-week data from the ASPIRE Phase 2B study at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting being held on May 4-8, 2025 in Salt Lake City, Utah. ARVO 2025 Presentation Details: Title: Safety and Efficacy of Senolytic Candidate UBX1325 for Diabetic Macular Edema: The BEHOLD Phase 2 and ASPIRE Phase 2b TrialsPresentation Number: 4014 Session: Diabetic Macular Edema: Anti-VEGF Date & Time: Wednesday, May 7,

      5/1/25 8:00:00 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME

      SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the peer-reviewed journal NEJM Evidence published results from the Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). As reported in the article titled, "Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema," the results suggested that the selective clearance of senescent cells in the retina provided disease-modifying and long-lasting improvements in vision in patients with DME, supporting the potential of UBX1325 as a novel

      4/23/25 8:00:00 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

      SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2025. UNITY announced 24-week and partial 36-week topline data from our Phase 2b ASPIRE study in diabetic macular edema (DME) in the first quarter. DME patients treated with UBX1325 (foselutoclax) showed vision improvements generally comparable to the aflibercept control, but the study did not meet the primary endpoint of statistical non-inferiority to aflibercept based on BCVA average at weeks 20 and 24. UBX1325 wa

      4/22/25 4:29:59 PM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Unity Biotechnology with a new price target

      Rodman & Renshaw initiated coverage of Unity Biotechnology with a rating of Buy and set a new price target of $8.00

      8/22/24 7:37:56 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unity Biotechnology upgraded by Wedbush with a new price target

      Wedbush upgraded Unity Biotechnology from Neutral to Outperform and set a new price target of $4.00 from $2.00 previously

      11/16/23 7:43:07 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unity Biotechnology upgraded by Roth Capital with a new price target

      Roth Capital upgraded Unity Biotechnology from Neutral to Buy and set a new price target of $4.00

      1/4/22 12:07:50 PM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CLO and Head of Ops Nguyen Alexander Hieu sold $18,388 worth of shares (17,852 units at $1.03), decreasing direct ownership by 27% to 48,753 units (SEC Form 4)

      4 - Unity Biotechnology, Inc. (0001463361) (Issuer)

      4/3/25 4:17:03 PM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO & Head of Corp. Dev. Sullivan Lynne Marie sold $22,523 worth of shares (21,867 units at $1.03), decreasing direct ownership by 18% to 98,905 units (SEC Form 4)

      4 - Unity Biotechnology, Inc. (0001463361) (Issuer)

      4/3/25 4:16:04 PM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Ghosh Anirvan sold $99,701 worth of shares (96,797 units at $1.03), decreasing direct ownership by 39% to 153,454 units (SEC Form 4)

      4 - Unity Biotechnology, Inc. (0001463361) (Issuer)

      4/3/25 4:15:04 PM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UBX
    Financials

    Live finance-specific insights

    See more
    • UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema

      Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidence interval), but did not meet statistical non-inferiority on the average of weeks 20 and 24, the primary analysis endpoint (met at 88% confidence interval) UBX1325-treated patients had a +5.2 letter gain in visual acuity at 24 weeks and a +5.5 letter gain at 36 weeks UBX1325 was numerically superior to aflibercept at 7 out of 10 time points in a pre-specified population with moderately aggressive disease UNITY to host investor call with retinal expert Robert B. Bhisi

      3/24/25 7:01:00 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema

      A single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in Best Corrected Visual Acuity (BCVA) of +6.2 ETDRS letters from baseline at 48 weeks Approximately 53% of UBX1325-treated patients did not require any additional injections through 48 weeks Retinal structure, as measured by central subfield thickness (CST), was maintained in UBX1325-treated patients throughout the duration of the study UBX1325 had a favorable safety and tolerability profile with no evidence of intraocular inflammation  UNITY to host investor call with retinal expert Robert B. Bhisitkul, M.D., Ph.D., today, April 24 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., April

      4/24/23 7:00:00 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

      UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm UBX1325 maintained visual acuity in patients with ongoing active disease through 24 weeks with less than one letter mean decrease from baseline 52% of UBX1325-treated patients did not require anti-VEGF treatment through 24 weeks Company to share 48-week BEHOLD DME data in April and intends to initiate Phase 2b study in DME in second half of 2023 UNITY to host investor call today, March 27, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company d

      3/27/23 7:30:00 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UBX
    Leadership Updates

    Live Leadership Updates

    See more
    • UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors

      SAN FRANCISCO, March 10, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Yehia Hashad, M.D., executive vice president of research and development and chief medical officer at Bausch + Lomb, has been appointed to the Company's board of directors and as a member of its science committee. "Dr. Hashad is a highly respected leader in ophthalmology whose expertise will be invaluable as we prepare for the upcoming Phase 2b ASPIRE 24-week data readout and optimize our strategy to potentially advance UBX1325 to late-stage development," said Anirvan Ghosh, Ph.

      3/10/25 8:00:00 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer

      SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today strengthened the executive leadership team with the appointment of Federico Grossi, M.D., Ph.D., as chief medical officer. Dr. Grossi brings a wealth of experience in clinical development and regulatory strategy in ophthalmology and other indications, most recently having led the development of SYFOVRE for geographic atrophy as chief medical officer at Apellis Pharmaceuticals. "Dr. Grossi's extensive experience in clinical strategy and a successful track record of advancing novel ophthalmolo

      1/6/25 8:00:00 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer

      SAN FRANCISCO, July 22, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Alicia Tozier, MBA, as chief strategy officer. In this new role, she will develop and implement the company's corporate and product strategies. "Alicia's impressive experience in ophthalmology product planning, commercial strategy, and scaling cross-functional teams will be instrumental in fortifying our strategies and capitalizing on the significant opportunity of UBX1325 to transform the treatment landscape for diabetic macular edema (DME)," said Anirvan Ghosh, Ph.

      7/22/24 8:00:00 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UBX
    SEC Filings

    See more
    • Unity Biotechnology Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Leadership Update, Financial Statements and Exhibits

      8-K - Unity Biotechnology, Inc. (0001463361) (Filer)

      5/5/25 8:00:09 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Unity Biotechnology Inc.

      10-Q - Unity Biotechnology, Inc. (0001463361) (Filer)

      4/22/25 4:31:19 PM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unity Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Unity Biotechnology, Inc. (0001463361) (Filer)

      4/22/25 4:30:08 PM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Unity Biotechnology Inc.

      SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)

      11/14/24 4:35:22 PM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Unity Biotechnology Inc. (Amendment)

      SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)

      2/14/24 1:52:24 PM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Unity Biotechnology Inc. (Amendment)

      SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)

      5/10/23 9:45:10 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care